Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECAD: Atorvastatin for CAD Prevention
NCT02245087Phase 2
Key facts
- Status
- Terminated
- Start
- Aug 2014
- Primary completion
- Sep 2019
- Countries
- 1
- Sponsor
- University Health Network
- Modality
- Small Molecules
- Drugs
- atorvastatin
- Conditions
- coronary artery disease (CAD)
01
Overview
Phase 2, randomised, open-label trial of atorvastatin in coronary artery disease (CAD) (2 arms), sponsored by University Health Network. Primary endpoint: Time to first occurrence of myocardial infarction, revascularization, stroke or death from any cause at 10 years. Started Aug 2014; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
Atorvastatin
Atorvastatin 20 mg daily
Guideline based care
Standard of care lipid management
03
Who it enrols
Healthy men (35-50) and women (45-59) with LDL > 1.8 mmol/L and at least one risk factor (obesity/hypertension, family history, South Asian ethnicity, or smoking). Excludes those with diabetes, active malignancy, or significant renal/hepatic dysfunction.
04
Endpoints
Primary
Time to first occurrence of myocardial infarction, revascularization, stroke or death from any cause
Beyond the preview
Go deeper on NCT02245087.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245087.